走貝爽 誌失益血税 郊戚神紫穣 遭窒 降妊拭 戚嬢 神潅 益 耕掘穿繰拭 魚虞 嬢汗 奄穣級戚 送娃羨 呪駁研 脊聖依昔走拭 企廃 軒匂闘亜 廃 装映紫 軒辞帖拭辞 蟹尽革推, 汝社拭 淫宿聖 砧壱 尻姥馬揮 曽鯉戚 匂敗鞠嬢 赤嬢辞 節獣 Fact幻 社鯵背球験艦陥.
ー舘奄旋生稽澗 Biosimilar, 舌奄旋生稽澗 郊戚神 重鉦 鯵降 穣端拭 爽鯉!---IBK 沿重費
誌失穿切税 郊戚神紫穣 遭窒精 舘奄旋生稽澗 Biosimilar 紫穣聖 域塙 箸精 遭楳 掻昔
穣端拭, 舌奄旋生稽澗 Biobetter研 匂敗廃 郊戚神 重鉦聖 鯵降 掻昔 穣端拭 園舛旋生稽
拙遂拝 穿諺戚陥.
舘奄旋生稽澗 Biosimilar 紫穣聖 慎是馬澗 淫恵爽税 爽亜 雌渋戚 穿諺吉陥. 戚澗 1) 誌
失穿切税 郊戚神 紫穣 遭窒聖 搭背 Biosimilar 獣舌税 失舌失引 古径亀亜 娃羨旋生稽
溌昔鞠醸壱, 2) 誌失穿切澗 Biosimilar 紫穣 歳醤拭辞澗 板降爽切虞壱 拝 呪 赤奄 凶庚
拭 戚研 魚虞説奄 是背 穿繰旋 託据税 昔呪蟹 薦妃亜 亜管拝 依生稽 毒舘鞠奄 凶庚戚陥.
薄仙 厩鎧拭辞 Biosimilar研 紫穣聖 層搾 掻昔 噺紫澗 漆闘軒紳, 疑焼薦鉦, LG持誤引
俳, 廃鉢追耕町 去戚 赤陥.
舌奄旋生稽澗 郊戚神 重鉦聖 鯵降 掻昔 淫恵爽税 奄穣 亜帖亜 穣益傾戚球吃 穿諺戚陥.
戚澗 1) 誌失穿切税 郊戚神紫穣 遭窒精 衣厩 郊戚神 重鉦 鯵降引 希災嬢 誌失税戟据税
帖戟紫穣, 奄糎 誌失穿切税 IT紫穣聖 奄鋼生稽 廃 税戟奄奄 紫穣税 獣格走 反引研 溌左
拝 依戚奄 凶庚戚壱, 2) 誌失穿切税 郊戚神 歳醤 R&D 昔覗虞亜 陥社 採膳馬奄 凶庚拭
奄糎 郊戚神 噺紫研 昔呪馬暗蟹 穿繰旋生稽 薦妃拝 亜管失戚 株壱, 3) 郊戚神 歳醤税 酔
呪廃 R&D 督戚覗虞昔聖 虞戚湿縮拝 亜管失亀 株奄 凶庚戚陥. 薄仙 厩鎧拭辞
Biobetter研 匂敗廃 郊戚神 重鉦聖 鯵降 掻昔 噺紫澗 廃臣郊戚神督原, 戚呪詔走什, 薦
学重 去戚 赤陥.―
慎厩域 穿庚 軒辞帖 奄淫拭辞 廃臣郊戚神 朕獄軒走拭 級嬢穐陥澗浦推...
悦汽 益 軒辞帖 切戟 左形檎 巷形 3500含君研 姥偽戟稽 鎧醤馬澗 噺紫虞壱馬革推........
Summary
GBI Research¨s new report, ＾Early Stage Drug Development in Disease Segments – Innovation Focuses on Stem Cell Therapies and Gene Therapies￣, provides an in-depth analysis of the unmet needs, drivers and barriers that affect the global Central Nervous System Disorders (CNS), Metabolic Disorders, Immunologic Disorders, Infection, Cardiovascular Disease and Oncology therapeutic markets. The report analyzes the early stage drug development that includes drugs under development in the discovery and preclinical stages of development for the above mentioned indications in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and the annual cost of therapy are forecast until 2017 for the key geographies in the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the Mergers and Acquisitions (M&A) and licensing agreements that shape the global market.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research¨s team of industry experts.
GBI Research finds that early stage drug development includes drugs under development in the discovery and preclinical stages of development. These studies are conducted in order to assess the safety and efficacy of the drug. This stage of development plays a key role in drug development as it determines potential molecules to be further processed for development by different companies. Increased strategies like RAS (Risk Assessment Strategies) issued by the US FDA (Food and Drug Administration) are persuading companies to implement safety scrutiny measures at early stages of development.
The majority of the molecules in the early stages of development are being developed for cancer indications. Molecules under development for breast cancer account for 23% of the total early stage development molecules under development for cancer. This is followed by prostate cancer, accounting for 20%, followed by colon cancer (15%).
Other than Oncology, other therapeutic areas with high activity in Research and Development (R&D) in early development phases include Central Nervous System (CNS) disorders, immunological disorders, and metabolic disorders. CNS disorders accounted for 14% of early stage drugs under development, followed by immunological disorders (13%) and metabolic disorders (10%). Compared to other therapeutic areas, there is less R&D activity in the metabolic disorders (9%) and infectious disease (9%) segments.
Scope
The scope of this report includes -
- Coverage of pipeline molecules in various discovery and pre-clinical phases of drug development along with pipeline analysis of the leading therapeutic segments, including Oncology, CNS disorders, immunological disorders, infection, metabolic disorders and cardiovascular disorders.
- Analysis of the above mentioned disorders market in the leading geographies of the world, which are the US, the UK, Germany, France, Italy, Spain and Japan.
- Key drivers and barriers that have a significant impact on the market.
- Competitive benchmarking of leading companies. The key companies studied in this report are Hanall Pharmaceutical Co. Ltd, Patrys Limited, F. Hoffmann-La Roche Ltd, Mirna Therapeutics, Inc. and Aphios Corporation.
- Key M&A activities and licensing agreements that have taken place between 2005 and 2010 in the global Oncology, CNS disorders, immunological disorders, infection, metabolic disorders and cardiovascular disorders markets.
Read more: http://www.reportlinker.com/p0397053/Early-Stage-Drug-Discovery-in-Disease-Segments-Innovation-Focuses-on-Stem-Cell-Therapies-and-Gene-Therapies.html#ixzz1FEF0a1u5
pharmaprojects拭 税背辞 厩鎧 R&D 1是 室域 38是稽 識舛吉汽 戚嬢辞, GBI拭辞亀 重鉦淫恵 噺紫 掻拭 政析馬惟 廃厩噺紫稽 朕獄軒走拭 臣串柔艦陥.
言左奄 凪戚走拭辞 蟹紳 推鉦 鎧遂精 是人 旭精汽 杭亜 税耕宿舌馬走 省蟹推 ??
希浦陥蟹 授辞亜 稽輯左陥 胡煽 嘉縛澗汽 巷充 税耕亜 眼移閃 赤澗依 旭奄亀 馬壱,,,,
ぞぞぞぞぞぞぞぞぞぞぞぞぞぞ
